Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206486265> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4206486265 endingPage "S264" @default.
- W4206486265 startingPage "S264" @default.
- W4206486265 abstract "Radical resection (RR), the current standard of care for MIUC, can be combined with neoadjuvant or adjuvant cisplatin-based therapy depending on cisplatin eligibility. This study assessed treatment patterns in MIUC in clinical practice in EU5 (France, Germany, Italy, Spain, UK), US, Canada, China, and Japan. Real-world descriptive data were drawn from the Adelphi MIUC Disease-Specific ProgrammeTM – a cross-sectional survey conducted between January-June 2021 with clinical/medical oncologists/urologists across in-scope geographies. Physicians extracted data from medical charts for 8 consecutive adult MIUC patients receiving RR. Demographics, clinical characteristics, and treatment patterns were described. A total of 320 physicians provided data on 2,178 MIUC patients. At MIUC diagnosis, mean age was 66.7 years. 73% of patients were male and 80% had primary tumour in bladder. Thirty-five percent of patients overall did not receive neoadjuvant or adjuvant therapy. This rate was lower in Germany (22%), and higher in Japan (63%) and Italy (45%). Overall, average proportion of patients receiving neoadjuvant therapy was 37%. This rate was lower in Italy (13%),and higher in Canada (63%), US (47%), and Spain (45%). Across all countries, 36% of patients received adjuvant therapy overall (range: 16% in Canada - 52% in Germany), most of which was platinum-based chemotherapy (77%), with most patients receiving one course (90%). A minority received immunotherapy (12%), with higher than average use in US (21%) and Germany (18%). Overall, average use of concurrent radiotherapy was 19% (5% in UK and Italy, 8% in Canada - 33% in China; 30% in Japan). Significant variation exists across countries in the MIUC treatment approach. Many eligible MIUC patients did not receive any neoadjuvant or adjuvant therapy in addition to RR. Further research on reasons for treatment choice may help further interpret the treatment patterns in these countries." @default.
- W4206486265 created "2022-01-26" @default.
- W4206486265 creator A5007674476 @default.
- W4206486265 creator A5009168027 @default.
- W4206486265 creator A5016227942 @default.
- W4206486265 creator A5065346343 @default.
- W4206486265 creator A5079215307 @default.
- W4206486265 creator A5080247056 @default.
- W4206486265 creator A5082973757 @default.
- W4206486265 creator A5090867847 @default.
- W4206486265 date "2022-01-01" @default.
- W4206486265 modified "2023-10-03" @default.
- W4206486265 title "POSC389 Characterisation of Existing Treatment Patterns in Muscle-Invasive Urothelial Carcinoma (MIUC) Across North America, Europe, and East Asia" @default.
- W4206486265 doi "https://doi.org/10.1016/j.jval.2021.11.1290" @default.
- W4206486265 hasPublicationYear "2022" @default.
- W4206486265 type Work @default.
- W4206486265 citedByCount "0" @default.
- W4206486265 crossrefType "journal-article" @default.
- W4206486265 hasAuthorship W4206486265A5007674476 @default.
- W4206486265 hasAuthorship W4206486265A5009168027 @default.
- W4206486265 hasAuthorship W4206486265A5016227942 @default.
- W4206486265 hasAuthorship W4206486265A5065346343 @default.
- W4206486265 hasAuthorship W4206486265A5079215307 @default.
- W4206486265 hasAuthorship W4206486265A5080247056 @default.
- W4206486265 hasAuthorship W4206486265A5082973757 @default.
- W4206486265 hasAuthorship W4206486265A5090867847 @default.
- W4206486265 hasBestOaLocation W42064862651 @default.
- W4206486265 hasConcept C126322002 @default.
- W4206486265 hasConcept C144024400 @default.
- W4206486265 hasConcept C149923435 @default.
- W4206486265 hasConcept C166957645 @default.
- W4206486265 hasConcept C191935318 @default.
- W4206486265 hasConcept C195910791 @default.
- W4206486265 hasConcept C205649164 @default.
- W4206486265 hasConcept C2776694085 @default.
- W4206486265 hasConcept C2777982462 @default.
- W4206486265 hasConcept C2780084366 @default.
- W4206486265 hasConcept C509974204 @default.
- W4206486265 hasConcept C71924100 @default.
- W4206486265 hasConceptScore W4206486265C126322002 @default.
- W4206486265 hasConceptScore W4206486265C144024400 @default.
- W4206486265 hasConceptScore W4206486265C149923435 @default.
- W4206486265 hasConceptScore W4206486265C166957645 @default.
- W4206486265 hasConceptScore W4206486265C191935318 @default.
- W4206486265 hasConceptScore W4206486265C195910791 @default.
- W4206486265 hasConceptScore W4206486265C205649164 @default.
- W4206486265 hasConceptScore W4206486265C2776694085 @default.
- W4206486265 hasConceptScore W4206486265C2777982462 @default.
- W4206486265 hasConceptScore W4206486265C2780084366 @default.
- W4206486265 hasConceptScore W4206486265C509974204 @default.
- W4206486265 hasConceptScore W4206486265C71924100 @default.
- W4206486265 hasIssue "1" @default.
- W4206486265 hasLocation W42064862651 @default.
- W4206486265 hasOpenAccess W4206486265 @default.
- W4206486265 hasPrimaryLocation W42064862651 @default.
- W4206486265 hasRelatedWork W1973373402 @default.
- W4206486265 hasRelatedWork W2022944059 @default.
- W4206486265 hasRelatedWork W2048191766 @default.
- W4206486265 hasRelatedWork W2371666691 @default.
- W4206486265 hasRelatedWork W2378355431 @default.
- W4206486265 hasRelatedWork W2384708512 @default.
- W4206486265 hasRelatedWork W2387970634 @default.
- W4206486265 hasRelatedWork W3029735720 @default.
- W4206486265 hasRelatedWork W4311068385 @default.
- W4206486265 hasRelatedWork W4322729359 @default.
- W4206486265 hasVolume "25" @default.
- W4206486265 isParatext "false" @default.
- W4206486265 isRetracted "false" @default.
- W4206486265 workType "article" @default.